Pre-made Elipovimab benchmark antibody ( Whole mAb, anti-HIV-1 gp120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-171

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-171 Category Tag

Product Details

Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the targeted elimination of HIV infected cells and is as of 2020 in phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.

Products Name (INN Index)

Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody

INN Name

Elipovimab

Target

HIV-1 gp120

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

4fq1:HL/4jy4:BA/4fqc:HL

Year Proposed

2018

Companies

Gilead Sciences

Conditions Approved

NA

Conditions Active

HIV infections

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

HIV-1 gp120

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide